Fmr LLC Buys 771 Shares of Innoviva, Inc. (NASDAQ:INVA)

Fmr LLC increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 8.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,119 shares of the biotechnology company’s stock after buying an additional 771 shares during the period. Fmr LLC’s holdings in Innoviva were worth $195,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Victory Capital Management Inc. lifted its stake in Innoviva by 3.5% in the third quarter. Victory Capital Management Inc. now owns 140,454 shares of the biotechnology company’s stock worth $2,712,000 after acquiring an additional 4,699 shares during the period. Segall Bryant & Hamill LLC bought a new stake in shares of Innoviva in the 3rd quarter valued at about $715,000. BOKF NA lifted its position in shares of Innoviva by 180.5% in the 2nd quarter. BOKF NA now owns 46,377 shares of the biotechnology company’s stock worth $761,000 after purchasing an additional 29,846 shares during the period. Caxton Associates LP boosted its stake in shares of Innoviva by 204.5% during the second quarter. Caxton Associates LP now owns 108,277 shares of the biotechnology company’s stock valued at $1,776,000 after purchasing an additional 72,716 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its stake in shares of Innoviva by 44.1% during the third quarter. Harbor Capital Advisors Inc. now owns 136,722 shares of the biotechnology company’s stock valued at $2,640,000 after purchasing an additional 41,827 shares in the last quarter. Institutional investors own 99.12% of the company’s stock.

Innoviva Stock Down 0.5 %

Shares of NASDAQ INVA opened at $17.84 on Friday. Innoviva, Inc. has a 12-month low of $14.32 and a 12-month high of $21.28. The stock’s fifty day simple moving average is $19.31 and its two-hundred day simple moving average is $18.51. The stock has a market capitalization of $1.12 billion, a PE ratio of 25.86 and a beta of 0.53. The company has a current ratio of 1.79, a quick ratio of 1.64 and a debt-to-equity ratio of 0.38.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.27 by ($0.25). Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The firm had revenue of $89.51 million for the quarter. As a group, analysts expect that Innoviva, Inc. will post 0.33 EPS for the current fiscal year.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.